Welcome to the international HTA database
Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year | Source | Title | |
---|---|---|---|
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Aliskiren (Rasilez®) for the treatment of essential hypertension | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | lisdexamfetamine dimesylate (Elvanse®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Ambrisentan (Volibris®) for pulmonary arterial hypertension | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Pazopanib (Votrient®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Eculizumab (Soliris®) for the treatment of paroxysmal nocturnal haemoglobinuria | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | 5-aminolaevulinic acid (Ameluz®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Maraviroc (Celsentri®) for treatment-experienced adults infected only with CCR5-tropic HIV-1 | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Anidulafungin (Ecalta®) for the treatment of invasive candidiasis in adult non-neutropenic patients | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Raltegravir (Isentress®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Nelarabine (Atriance®) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tegafur/gimeracil/oteracil (Teysuno®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Botulinum toxin type A (Botox®) | |
2014 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Atomoxetine (Strattera®) | |
2009 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) for the treatment of HIV-1 infection in adults | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Etanercept (Enbrel®) | |
2014 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Abatacept (Orencia®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Alemtuzumab (MabCampath®) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Saxagliptin (Onglyza®) | |
2014 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Linaclotide (Constella®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-experienced patients | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Lixisenatide (Lyxumia®) | |
2014 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Nalmefene (Selincro®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Sodium phenylbutyrate (Pheburane®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture | |
2013 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Etravirine (Intelence®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Abacavir 600mg/lamivudine 300mg (Kivexa®) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Rufinamide (Inovelon®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Icatibant acetate (Firazyr®) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tacrolimus prolonged-release (Advagraf®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Pegfilgrastim (Neulasta®) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Trabectedin (Yondelis®) for advanced soft tissue sarcoma | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tenofovir disoproxil fumarate (Viread®) for the treatment of hepatitis B | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Buprenorphine/naloxone (Suboxone®) as substitution treatment for opioid dependence | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Ziconotide (Prialt®) for the intrathecal treatment of severe, chronic pain | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Deferasirox (Exjade®) for the treatment of chronic iron overload due to blood transfusions | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Docetaxel (Taxotere®) for locally advanced squamous cell carcinoma of the head and neck | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Lenalidomide (Revlimid®) for multiple myeloma | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Fondaparinux Sodium (Arixtra®) for the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Fondaparinux Sodium (Arixtra®) for the treatment of ST segment elevation myocardial infarction (STEMI) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Intravenous topotecan (Hycamtin®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Intravenous topotecan (Hycamtin®) | |
2008 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Epoetin delta (Dynepo®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dasatinib (Sprycel®) for the treatment of Lymphoid blast CML and PH+ ALL | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dasatinib (Sprycel®) for the treatment of chronic, accelerated or blast phase chronic myeloid leukaemia | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Vinorelbine (Navelbine Oral®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Idursulfase (Elaprase®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Agalsidase alfa (Replagal®) | |
2012 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Insulin detemir (Levemir®) 100 U/ml solution for injection | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Sunitinib (Sutent®) | |
2012 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Fidaxomicin (Dificlir®) 200 mg film-coated tablets | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Darunavir (Prezista®) | |
2012 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Degarelix (Firmagon®) 80 mg and 120 mg subcutaneous injection | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tipranavir (Aptivus®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Co-careldopa intestinal gel (Duodopa®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Dexrazoxane (Savene®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Clofarabine (Evoltra®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Emtricitabine (Emtriva®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Emtricitabine/tenofovir DF (Truvada®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Parathyroid hormone (PTH) (Preotact®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of sorafenib (Nexavar®) for advanced renal cell carcinoma within NHS Wales | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of alglucosidase alfa (Myozyme™) within NHS Wales | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of sodium phenylbutyrate within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Riociguat (Adempas®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Laronidase (Aldurazyme®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Rituximab (MabThera®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Lisdexamfetamine dimesylate (Elvanse Adult®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Enfuvirtide | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Ponatinib (Iclusig®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Riociguat (Adempas®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Anagrelide (Xagrid®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Umeclidinium (Incruse®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Enzalutamide (Xtandi®) | |
2007 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of iloprost trometamol (Ventavis®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Leuprorelin acetate (Prostap® SR DCS/Prostap® 3 DCS) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tacrolimus (Envarsus®) | |
2006 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of agalsidase beta (Fabrazyme®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Olodaterol (as hydrochloride) (Striverdi® Respimat®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Pomalidomide (Imnovid®) | |
2006 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of adalimumab (Humira®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Cabozantinib (Cometriq®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Brimonidine (Mirvaso®) | |
2006 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of cetuximab (Erbitux®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Follitropin alfa (Bemfola®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Beclometasone dipropionate/formoterol fumarate (Fostair®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Magnesium aspartate dihydrate (Magnaspartate) | |
2006 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of mycophenolic acid as a sodium salt (Myfortic®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Lurasidone (Latuda®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Brentuximab vedotin (Adcetris®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Rarunavir/cobicistat (Rezolsta®) | |
2006 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of liposomal cytarabine (DepoCyte®) within NHS Wales | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Infliximab (Remsima®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Adalimumab (Humira®) | |
2005 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Use of Pegvisomant (Somavert®) within NHS Wales | |
2014 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Tenofovir disoproxil fumarate (Viread®) | |
2015 | All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) | Infliximab (Inflectra®) |